Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CORON-ACT - a Multicenter, Double-blind, Randomized Controlled Phase II Trial on the Efficacy and Safety of Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)

Next Previous
Trial Profile

CORON-ACT - a Multicenter, Double-blind, Randomized Controlled Phase II Trial on the Efficacy and Safety of Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications COVID 2019 infections; COVID-19 pneumonia; SARS-CoV-2 acute respiratory disease
  • Focus Therapeutic Use
  • Acronyms CORON-ACT

Most Recent Events

  • 12 Oct 2020 Status changed from recruiting to discontinued as it was not possible to recruit the planned number of patients during the planned study period and "Dexamethason" was included in the standard of care for the study population during the courseof the study and inclusion criteria could no longer be met.
  • 22 Apr 2020 Status changed from not yet recruiting to recruiting.
  • 07 Apr 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top